Pubblicazioni scientifiche

Nuvola G.; Rizzo A.; Mollica V.; Massari F., The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?, «IMMUNOTHERAPY», 2022, 14, pp. 171 - 174 [Articolo in rivista]

Santoni M.; Molina-Cerrillo J.; Massari F.; Montironi R.; Grande E., Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study, «EUROPEAN UROLOGY», 2022, 81, pp. 623 - 624 [Articolo in rivista]

Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F., Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis, «EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH», 2022, 22, pp. 45 - 51 [Articolo in rivista]

Rizzo A.; Mollica V.; Santoni M.; Massari F., Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, pp. 1 - 3 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Santoni M.; Palmiotti G.; Massari F., Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, pp. 1 - 8 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Merler S.; Morelli F.; Sorgentoni G.; Oderda M.; Santoni M.; Massari F., Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2022, 18, pp. 235 - 240 [Articolo in rivista]

Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R., Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis, «EUROPEAN JOURNAL OF CANCER», 2022, 177, pp. 175 - 185 [Articolo in rivista]

Rebuzzi S.E.; Signori A.; Stellato M.; Santini D.; Maruzzo M.; De Giorgi U.; Pedrazzoli P.; Galli L.; Zucali P.A.; Fantinel E.; Carella C.; Procopio G.; Milella M.; Boccardo F.; Fratino L.; Sabbatini R.; Ricotta R.; Panni S.; Massari F.; Soraru M.; Santoni M.; Cortellini A.; Prati V.; Soto Parra H.; Atzori F.; Di Napoli M.; Caffo O.; Messina M.; Morelli F.; Prati G.; Nole F.; Vignani F.; Cavo A.; Roviello G.; Llaja Obispo M.A.; Porta C.; Buti S.; Fornarini G.; Banna G.L., The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis, «FRONTIERS IN ONCOLOGY», 2022, 12, pp. 1 - 15 [Articolo in rivista] Open Access

Rizzo A.; Mollica V.; Massari F., Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma, «JAMA ONCOLOGY», 2022, 8, pp. 783 - 784 [Articolo in rivista]

Pal S.K.; Uzzo R.; Karam J.A.; Master V.A.; Donskov F.; Suarez C.; Albiges L.; Rini B.; Tomita Y.; Kann A.G.; Procopio G.; Massari F.; Zibelman M.; Antonyan I.; Huseni M.; Basu D.; Ci B.; Leung W.; Khan O.; Dubey S.; Bex A., Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial, «THE LANCET», 2022, 400, pp. 1103 - 1116 [Articolo in rivista] Open Access

Brunelli M.; Martignoni G.; Malpeli G.; Volpe A.; Cima L.; Raspollini M.R.; Barbareschi M.; Tafuri A.; Masi G.; Barzon L.; Ammendola S.; Villanova M.; Cerruto M.A.; Milella M.; Buti S.; Bersanelli M.; Fornarini G.; Rebuzzi S.E.; Vellone V.G.; Gaggero G.; Procopio G.; Verzoni E.; Bracarda S.; Fanelli M.; Sabbatini R.; Passalacqua R.; Perrucci B.; Giganti M.O.; Donini M.; Panni S.; Tucci M.; Prati V.; Ortega C.; Calio A.; Eccher A.; Alongi F.; Pappagallo G.; Iacovelli R.; Mosca A.; Umari P.; Montagnani I.; Gobbo S.; Atzori F.; Munari E.; Maruzzo M.; Basso U.; Pierconti F.; Patriarca C.; Colombo P.; Lapini A.; Conti G.; Salvioni R.; Bollito E.; Cossarizza A.; Massari F.; Rizzo M.; Franco R.; Zito-Marino F.; Plata Y.A.; Galuppini F.; Sbaraglia M.; Fassan M.; Dei Tos A.P.; Colecchia M.; Moch H.; Scaltriti M.; Porta C.; Delahunt B.; Giannarini G.; Bortolus R.; Rescigno P.; Banna G.L.; Signori A.; Obispo M.A.L.; Perris R.; Antonelli A., Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study, «JOURNAL OF PERSONALIZED MEDICINE», 2022, 12, pp. 1 - 15 [Articolo in rivista] Open Access

Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M., Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy, «CANCER MANAGEMENT AND RESEARCH», 2022, 14, pp. 1945 - 1960 [Articolo in rivista] Open Access

Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F., Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw, «CURRENT ONCOLOGY», 2022, 29, pp. 1709 - 1722 [Articolo in rivista] Open Access

Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.; Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F., Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma, «TARGETED ONCOLOGY», 2022, 17, pp. 61 - 68 [Articolo in rivista]

Santoni M.; Rizzo A.; Mollica V.; Matrana M.R.; Rosellini M.; Faloppi L.; Marchetti A.; Battelli N.; Massari F., The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 170, pp. 103596 - 103603 [Articolo in rivista]

Righini M.; Mollica V.; Rizzo A.; La Manna G.; Massari F., Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, pp. 1 - 17 [Articolo in rivista] Open Access

Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmiotti G.; Massari F., The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis, «JOURNAL OF PERSONALIZED MEDICINE», 2022, 12, pp. 1 - 8 [Articolo in rivista] Open Access

Molina-Cerrillo J.; Santoni M.; Ruiz A.; Massari F.; Pozas J.; Ortego I.; Gomez V.; Grande E.; Alonso-Gordoa T., Epigenetics in advanced renal cell carcinoma: Potential new targets, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 180, pp. 103857 - 103866 [Articolo in rivista]

Nigro M.C.; Mollica V.; Marchetti A.; Cheng M.; Rosellini M.; Montironi R.; Cheng L.; Massari F., Current androgen receptor antagonists under investigation for resistant prostate cancer, «EXPERT REVIEW OF ANTICANCER THERAPY», 2022, 22, pp. 191 - 202 [Articolo in rivista]

Rizzo A.; Mollica V.; Santoni M.; Massari F., Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 482 - 487 [Articolo in rivista]